Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AHCY | P23526 | 10/20 | 1.00 |
| ▸ | ADORA2A | P29274 | 7/20 | 1.00 |
| ▸ | ADORA1 | P30542 | 5/20 | 0.71 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.66 |
| ▸ | PI4KA | P42356 | 2/20 | 0.58 |
| ▸ | PI4K2B | Q8TCG2 | 2/20 | 0.58 |
| ▸ | PI4K2A | Q9BTU6 | 2/20 | 0.58 |
| ▸ | PI4KB | Q9UBF8 | 2/20 | 0.58 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.57 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| (S)-Dhpa SCHEMBL936287 | 1.00 | AHCY (1.00) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| (S)-Dhpa SCHEMBL28605202 | 1.00 | AHCY (1.00) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL16603993 | 0.92 | AHCY (0.85) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL13394191 | 0.88 | AHCY (0.79) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL28068456 | 0.88 | AHCY (0.78) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL2556536 | 0.87 | AHCY (0.76) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL14963614 | 0.87 | ADORA2A (0.76) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL2556539 | 0.87 | AHCY (0.76) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL13394189 | 0.87 | ADORA2A (0.76) | AHCYADORA2AADORA1ALDH1A1PI4KA | |
| SCHEMBL11474105 | 0.87 | AHCY (0.76) | AHCYADORA2AADORA1ALDH1A1PI4KA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 154 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230110614-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | ATOSSA THERAPEUTICS, INC. | 2023-04-13 | — | — | US | claimed |
| EP-4125936-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | Atossa Therapeutics, Inc. (US) | 2023-02-08 | — | — | EP | claimed |
| WO-2021194890-A1 | HEPARIN AND N-ACETYLCYSTEINE FOR THE TREATMENT OF A RESPIRATORY VIRUS | ATOSSA THERAPEUTICS, INC. (US) | 2021-09-30 | — | — | WO | claimed |
| US-20210299143-A1 | USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES | Spectral Analytics, Inc. (US) | 2021-09-30 | — | — | US | claimed |
| US-20150057243-A1 | Compositions and Methods for the Inhibition of Methyltransferases | NORTHERN UNIVERSITY (US) | 2015-02-26 | — | — | US | claimed |
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2013-01-24 | — | — | US | claimed |
| EP-2513298-A2 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | President and Fellows of Harvard College (US) | 2012-10-24 | — | — | EP | claimed |
| WO-2011075665-A2 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | PRESIDENT AND FELLOWS OF HARVARD COLLEGE (US) | 2011-06-23 | — | — | WO | claimed |
| EP-0539493-B1 | TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES | BODOR NICHOLAS S (US) | 1997-03-26 | — | — | EP | claimed |
| EP-0577725-A4 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIV FLORIDA (US) | 1996-04-17 | — | — | EP | claimed |
| WO-1992017185-A1 | TARGETED DRUG DELIVERY VIA MIXED PHOSPHATE DERIVATIVES | UNIVERSITY OF FLORIDA (US) | 1992-10-15 | — | — | WO | claimed |
| US-5087618-A | Antiviral, anticancer, antitumor agents | UNIVERSITY OF FLORIDA (US) | 1992-02-11 | — | — | US | claimed |
| WO-1992000988-A1 | TARGETED DRUG DELIVERY VIA PHOSPHONATE DERIVATIVES | BODOR NICHOLAS S (US) | 1992-01-23 | — | — | WO | claimed |
| EP-0262696-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1988-04-06 | — | — | EP | claimed |
| EP-0222425-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-20 | — | — | EP | claimed |
| EP-0221588-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-05-13 | — | — | EP | claimed |
| EP-0218300-A2 | Brain-specific drug delivery | UNIVERSITY OF FLORIDA (US) | 1987-04-15 | — | — | EP | claimed |
| EP-0110955-A1 | BRAIN-SPECIFIC DRUG DELIVERY. | UNIV FLORIDA (US) | 1984-06-20 | — | — | EP | claimed |
| WO-1983003968-A1 | BRAIN-SPECIFIC DRUG DELIVERY | UNIVERSITY OF FLORIDA (US) | 1983-11-24 | — | — | WO | claimed |
| US-4230708-A | SYNERGISTIC | STICHTING REGA V.Z.W. (BE) | 1980-10-28 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130023491-A1 | BETA-CELL REPLICATION PROMOTING COMPOUNDS AND METHODS OF THEIR USE | ADK, AHCY, IAPP | AHCY 2/4885ADORA2A 169/4885ADORA1 330/4885 |
| US-20150057243-A1 | Compositions and Methods for the Inhibition of Methyltransferases | RNMT, EMG1, NSUN2 | AHCY 33/4885ADORA2A 3039/4885ADORA1 3989/4885 |
| US-20210299143-A1 | USE OF ANTAGONISTS TO THE NUCLEAR STEROID RECEPTOR TO INHIBIT CORONAVIRUSES | NCOA1, NCOA2, NCOA3 | AHCY 3060/4885ADORA2A 2496/4885ADORA1 2642/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.